Stockpolly
Search
Delisting risk
APVO · NASDAQ · Biotechnology

Aptevo Therapeutics (APVO)

Developer of multispecific cancer immunotherapies and radiopharmaceutical oncology programs.

$2.32
Pre-market−0.30 (−11.63%)
At close$2.62(+11.97%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
767656668676
Research & development444434434444
333223334233
General & administrative333223334233
Other expenses000000000000
Operating income−7−6−7−6−5−6−6−6−8−6−7−6
000000000000
Other non-operating income000000000000
Income before tax−6−6−7−6−5−6−6−6−8−6−7−6
Net income from continuing operations−6−6−7−6−5−6−6−6−8−6−7−6
Discontinued operations000000000000
Net income−6−6−7−6−5−6−6−6−8−6−7−6
EPS, basic−$295,114.00−$177,705.00−$132,553.00−$22,262.00−$6,441.29−$1,558.04−$1,581.72−$151.29−$40.13−$159.33−$6.41−$5.31
EPS, diluted−$295,114.00−$177,705.00−$132,553.00−$22,262.00−$6,441.29−$1,558.04−$1,581.72−$151.29−$40.13−$159.33−$6.41−$5.31
Weighted average shares, basic0————0000111
Weighted average shares, diluted0————0000111
EBITDA−6−6−7−6−5−6−6−6−8−6−7−7
Depreciation & amortization000000000000
EBIT−7−6−7−6−5−6−6−6−8−6−7−7